Scientists at Helmholtz Zentrum fur Infektionsforschung GmbH and Lead Discovery Center GmbH have identified α-hemolysin (Staphylococcus aureus) inhibitors reported to be useful for the treatment of staphylococcal pneumonia.
The industry is looking, with renewed hope, to the “promise” of messenger RNA (mRNA) therapeutics for a wide range of diseases beyond COVID-19, and not only in vaccine form but also for gene and cell therapies.
Having secured a 40% price cut and a commitment to not enforce a patent protecting a tuberculosis drug, South Africa’s Competition Commission decided not to prosecute a complaint accusing Johnson & Johnson (J&J) and its subsidiary, Janssen Pharmaceutica (Pty) Ltd., of anticompetitive conduct.
Hillevax Inc. is turning its attention to preventing moderate or severe acute gastroenteritis events (AGEs) in adults with norovirus after the phase IIb NEST-IN1 trial testing virus-like particle-based vaccine HIL-214 in infants missed its primary and secondary endpoints, news that sent shares of the company (NASDAQ:HLVX) plummeting 88% to close July 8 at $1.64, a significant drop from the IPO price of $17 two years ago.
SRI International has divulged lipoxygenase inhibitors, particularly polyunsaturated fatty acid 5-lipoxygenase (ALOX5) and/or ALOX15, reported to be useful for the treatment of bacterial infections.
Researchers from Columbia University and collaborators described the mechanism used by mAb 77, a single-chain variable fragment (scFv) derived from monoclonal antibody (mAb 77.4) targeting MeV F peptide, to neutralize viral infection.
Curevac AG is casting off the deadweight of its pandemic push to translate its mRNA technology into a marketed COVID-19 vaccine, in a new €1.45 billion (US$1.6 billion) deal in which GSK plc will acquire full rights to infectious disease vaccines the two were co-developing.
Pfizer Inc. has identified nonstructural protein 3 (nsp3; PLpro) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 (COVID-19) infection.
Tonix Pharmaceuticals Holding Corp. has been awarded up to $34 million over 5 years under a contract with the U.S. Department of Defense (DoD)’s Defense Threat Reduction Agency (DTRA).
RSS
